Idera Pharmaceuticals Inc
F:HXXB
Fundamental Analysis

Revenue & Expenses Breakdown
Idera Pharmaceuticals Inc
Balance Sheet Decomposition
Idera Pharmaceuticals Inc
Current Assets | 17.9m |
Cash & Short-Term Investments | 12m |
Receivables | 4.2m |
Other Current Assets | 1.6m |
Non-Current Assets | 83.2m |
PP&E | 544k |
Intangibles | 82.7m |
Free Cash Flow Analysis
Idera Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Idera Pharmaceuticals Inc
Revenue
|
4.9m
USD
|
Operating Expenses
|
-24.4m
USD
|
Operating Income
|
-19.5m
USD
|
Other Expenses
|
-3.8m
USD
|
Net Income
|
-23.4m
USD
|
HXXB Profitability Score
Profitability Due Diligence
Idera Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Idera Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
HXXB Solvency Score
Solvency Due Diligence
Idera Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Idera Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HXXB Price Targets Summary
Idera Pharmaceuticals Inc
Dividends
Current shareholder yield for HXXB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?